home / stock / goss / goss news

GOSS News and Press, Gossamer Bio Inc. From 07/13/22

Stock Information
Company Name: Gossamer Bio Inc.
Stock Symbol: GOSS
Market: NYSE
Website: gossamerbio.com
Menu
GOSS GOSS Quote GOSS Short GOSS News GOSS Articles GOSS Message Board
Get GOSS Alerts

News, Short Squeeze, Breakout and More Instantly...
GOSS - XORTX Therapeutics leads healthcare gainers, Humanigen and Atara Biotherapeutics among losers

Gainers: XORTX Therapeutics ( XRTX ) +39% . Gossamer Bio ( GOSS ) +24% . Rhythm Pharmaceuticals ( RYTM ) +23% . Apollo Endosurgery ( APEN ) +18% . Tyra Biosciences ( TYRA ) +15% . Losers: Humanigen ( HGEN ) -80% . Atara Biotherap...
GOSS - Gossamer Bio to raise $120 in a private equity placement

Gossamer Bio ( NASDAQ: GOSS ) to sell approximately 16.6M shares of its common stock at $7.21/share in a private placement. Gross proceeds are expected to be approximately $120M. The financing is expected to close on July 15. “We are very pleased this high-q...

GOSS - Gossamer Bio Announces $120 Million Private Placement Financing

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced today it has agreed to sell approximately 16.6 million sh...

GOSS - REAL,COMM and OVID among after hour movers

Gainers: Cowen ( COWN ) +16% . CommScope Holding Company ( COMM ) +5% . Red Robin Gourmet Burgers ( RRGB ) +3% . The RealReal ( REAL ) +2% . AbCellera Biologics ( ABCL ) +2% . Losers: Nyxoah ( NYXH ) -7% . Ovi...
GOSS - Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib's Potential for the Treatment of PAH

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of key preclinical data supporting ...

GOSS - ISPO, RDBX and GOSS are among after hour movers

Gainers: Inspirato Incorporated (ISPO) +17%. Sonos (SONO) +15%. Bumble  (BMBL) +12%. Aemetis (AMTX) +5%. Enovix Corporation (ENVX) +5%. Losers: Beyond Meat (BYND) -21%. Fossil Group (FOSL) -15%. Fluence Energy (FLNC) -15%. Redbox Entertai...

GOSS - Gossamer Bio GAAP EPS of -$0.76 in-line

Gossamer Bio press release (NASDAQ:GOSS): Q1 GAAP EPS of -$0.76 in-line. Cash, cash equivalents & marketable securities totaled $272 million as of March 31, 2022. For further details see: Gossamer Bio GAAP EPS of -$0.76 in-line

GOSS - Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update

- Seralutinib (GB002) completed PAH patient enrollment in Phase 2 TORREY Study - - Topline results from Phase 2 TORREY Study expected in the fourth quarter of 2022 - - Cash, cash equivalents & marketable securities totaled $272 million as of March 31, 2022 - ...

GOSS - Gossamer stock slumps 12% as HC Wainwright/Barclays cut price target following phase 2 trial miss

Gossamer Bio (NASDAQ:GOSS) saw a slew of price cuts from firms after the company's drug GB004 failed a phase 2 trial in mild-to-moderate active ulcerative colitis (UC). H.C. Wainwright analyst Patrick Trucchio lowered the firm's price target on Gossamer to $20 from $25 and kept a Buy rating o...

GOSS - Nkarta, ERYTECH Pharma top healthcare gainers; Eliem, Clarus lead losers' pack

Gainers: Nkarta (NKTX) +84%. ERYTECH Pharma (ERYP) +54%. Sunshine Biopharma (SBFM) +25%. Rubius Therapeutics (RUBY) +17%. Quoin Pharmaceuticals (QNRX) +12%. Losers: Eliem Therapeutics (ELYM) -55%. Clarus Therapeutics Holdings (CRXT) -54%....
Previous 10 Next 10